Hans C. Andersson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Hans C. Andersson has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
- Erika Vucko
Ann & Robert H. Lurie Children's Hospital, Chicago, IL, USA
2 shared publications - Kea Crivelly
Hayward Genetics Center, Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, LA 70112, USA
2 shared publications - Leah B. Wessenberg
OHSU Doernbecher Children's Hospital, Portland, OR, USA
2 shared publications - Melissa Lah
Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, USA
2 shared publications - Stephanie Sacharow
Boston Children's Hospital, Boston, MA, USA
2 shared publications Alston E. Dunbar
Department of Pediatrics
1 shared publication
Latest Publications
- Open Access
- 9 December 2025
- Published by MDPI AG in International Journal of Neonatal Screening
- Vol. 11 (4) , 112
Expanded Newborn Screening for Inborn Errors of Metabolism at a Single Center in Louisiana (2005–2024): Outcomes
This study evaluates the incidence of metabolic disorders detected from January 2005 to December 2024 and their clinical outcomes. Data were retrospectively collected from the Louisiana Newborn Screening database. Clinical outcomes were obtained through review of corresponding medical records. In addition, an electronic questionnaire assessing educational attainment and neurodevelopmental disorders was sent to the patients’ families. Of 1,230,356 infants screened, 478 were diagnosed with metabolic disorders, corresponding to an incidence of 1 in 2574 live births. The three most commonly identified conditions were biotinidase deficiency, phenylketonuria (PKU), and medium-chain acyl-CoA dehydrogenase deficiency (MCADD). During the study period, at least 11 patients died. The program demonstrated a false-positive rate of 0.93%. Twelve patients (7%) were symptomatic before or at the time of NBS result notification. Recurrent metabolic decompensations occurred in 3 of 4 maple syrup urine disease (MSUD) cases, 7 of 7 methylmalonic acidemia (MMA) cases, 1 of 4 propionic acidemia (PA) cases and 1 of 7 urea cycle defect cases. Regarding long-term outcomes, 45.7% of survey respondents reported adverse neurodevelopmental outcomes of varying severity. Early detection and timely intervention have contributed to normal or near-normal outcomes in many cases. However, the morbidity and mortality observed in some patients despite early diagnosis highlights the severity and complexity of certain metabolic conditions. Additionally, the relatively high false positive rate underscores the need for ongoing efforts to improve the specificity of screening protocols to reduce unnecessary follow-ups and mitigate potential stress for families.
- 9 December 2025
- Published by MDPI AG in International Journal of Neonatal Screening
- Vol. 11 (4) , 112
Open AccessExpanded Newborn Screening for Inborn Errors of Metabolism at a Single Center in Louisiana (2005–2024): Outcomes
This study evaluates the incidence of metabolic disorders detected from January 2005 to December 2024 and their clinical outcomes. Data were retrospectively collected from the Louisiana Newborn Screening database. Clinical outcomes were obtained through review of corresponding medical records. In addition, an electronic questionnaire assessing educational attainment and neurodevelopmental disorders was sent to the patients’ families. Of 1,230,356 infants screened, 478 were diagnosed with metabolic disorders, corresponding to an incidence of 1 in 2574 live births. The three most commonly identified conditions were biotinidase deficiency, phenylketonuria (PKU), and medium-chain acyl-CoA dehydrogenase deficiency (MCADD). During the study period, at least 11 patients died. The program demonstrated a false-positive rate of 0.93%. Twelve patients (7%) were symptomatic before or at the time of NBS result notification. Recurrent metabolic decompensations occurred in 3 of 4 maple syrup urine disease (MSUD) cases, 7 of 7 methylmalonic acidemia (MMA) cases, 1 of 4 propionic acidemia (PA) cases and 1 of 7 urea cycle defect cases. Regarding long-term outcomes, 45.7% of survey respondents reported adverse neurodevelopmental outcomes of varying severity. Early detection and timely intervention have contributed to normal or near-normal outcomes in many cases. However, the morbidity and mortality observed in some patients despite early diagnosis highlights the severity and complexity of certain metabolic conditions. Additionally, the relatively high false positive rate underscores the need for ongoing efforts to improve the specificity of screening protocols to reduce unnecessary follow-ups and mitigate potential stress for families.
- Open Access
- 26 December 2024
- Published by Elsevier in Molecular Genetics and Metabolism Reports
- Vol. 42, 101181
Lessons learned from 5 years of pegvaliase in US clinics: A case series
- 26 December 2024
- Published by Elsevier in Molecular Genetics and Metabolism Reports
- Vol. 42, 101181
Open AccessLessons learned from 5 years of pegvaliase in US clinics: A case series
- Open Access
- 3 February 2024
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 141 (3) , 108152
Outcomes in 14 live births resulting from Pegvaliase-treated pregnancies in PKU-affected females
- 3 February 2024
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 141 (3) , 108152
Open AccessOutcomes in 14 live births resulting from Pegvaliase-treated pregnancies in PKU-affected females
- Open Access
- 14 August 2021
- Published by Elsevier in Molecular Genetics and Metabolism Reports
- Vol. 28, 100790
Use of pegvaliase in the management of phenylketonuria: Case series of early experience in US clinics
- 14 August 2021
- Published by Elsevier in Molecular Genetics and Metabolism Reports
- Vol. 28, 100790
Open AccessUse of pegvaliase in the management of phenylketonuria: Case series of early experience in US clinics
- 1 January 2018
- Published by Elsevier in The Journal of Pediatrics
- Vol. 192, 265
Stippled Chondral Calcifications of the Patella in Zellweger Syndrome
- 1 January 2018
- Published by Elsevier in The Journal of Pediatrics
- Vol. 192, 265
Stippled Chondral Calcifications of the Patella in Zellweger Syndrome
- 1 November 2017
- Published by Elsevier in The Journal of Pediatrics
- Vol. 190, 9-10
Newborn Screening for Spinal Muscular Atrophy and Lysosomal Storage Disorders Takes Advantage of Novel Therapies
- 1 November 2017
- Published by Elsevier in The Journal of Pediatrics
- Vol. 190, 9-10
Newborn Screening for Spinal Muscular Atrophy and Lysosomal Storage Disorders Takes Advantage of Novel Therapies
- 1 April 2015
- Published by Elsevier in The Journal of Pediatrics
- Vol. 166 (4) , 800-801
Newborn Screening + Enzyme Replacement Therapy = Improved Lysosomal Storage Disorder: Outcomes in Infantile-Onset Pompe Disease
- 1 April 2015
- Published by Elsevier in The Journal of Pediatrics
- Vol. 166 (4) , 800-801
Newborn Screening + Enzyme Replacement Therapy = Improved Lysosomal Storage Disorder: Outcomes in Infantile-Onset Pompe Disease
- Open Access
- 14 October 2014
- Published by Elsevier in Molecular Genetics and Metabolism Reports
- Vol. 1, 451-454
A SUCLG1 mutation in a patient with mitochondrial DNA depletion and congenital anomalies
- 14 October 2014
- Published by Elsevier in Molecular Genetics and Metabolism Reports
- Vol. 1, 451-454
Open AccessA SUCLG1 mutation in a patient with mitochondrial DNA depletion and congenital anomalies
- 1 October 2011
- Published by Elsevier in Genetics in Medicine
- Vol. 13 (10) , 903-907
Emergency preparedness for genetics centers, laboratories, and patients: The Southeast Region Genetics Collaborative strategic plan
- 1 October 2011
- Published by Elsevier in Genetics in Medicine
- Vol. 13 (10) , 903-907
Emergency preparedness for genetics centers, laboratories, and patients: The Southeast Region Genetics Collaborative strategic plan
- 1 December 2008
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 122 (6) , 1182-1190
Eight-Year Clinical Outcomes of Long-Term Enzyme Replacement Therapy for 884 Children With Gaucher Disease Type 1
OBJECTIVE. The goal was to analyze the clinical responses to enzyme replacement therapy with alglucerase or imiglucerase in a large international cohort of children with Gaucher disease type 1. METHODS. Anonymized data from 884 children in the International Collaborative Gaucher Group Gaucher Registry were analyzed to determine the effects of long-term enzyme replacement therapy with alglucerase or imiglucerase on hematologic and visceral manifestations, linear growth, and skeletal disease. The parameters measured were hemoglobin levels, platelet counts, spleen and liver volumes, z scores for height and bone mineral density, and reports of bone pain and bone crises. RESULTS. The median height z score for the study population was −1.4 at baseline. After 8 years of treatment, the median height approximated the median value for the normal population. Anemia, although not severe, was present in >50% of patients at baseline and resolved for all patients after 8 years of treatment. More than 50% of patients had platelet counts of 95% had platelet counts above this level after 8 years of treatment. Liver and spleen volumes decreased over 8 years of treatment. The mean bone mineral density z score was −0.34 at baseline, and values normalized within 6.6 years of treatment. Seventeen percent of patients reported a bone crisis before treatment and in the first 2 years of treatment, but no bone crises were reported after 2 years of enzyme replacement therapy. Few patients (2.5%) without bone crises before enzyme replacement therapy had a crisis after the start of treatment. CONCLUSIONS. These longitudinal data quantitate the benefits of continuous enzyme replacement therapy with alglucerase/imiglucerase for children with Gaucher disease type 1. Within 8 years of enzyme replacement therapy, most clinical parameters studied became normal or nearly normal.
- 1 December 2008
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 122 (6) , 1182-1190
Eight-Year Clinical Outcomes of Long-Term Enzyme Replacement Therapy for 884 Children With Gaucher Disease Type 1
OBJECTIVE. The goal was to analyze the clinical responses to enzyme replacement therapy with alglucerase or imiglucerase in a large international cohort of children with Gaucher disease type 1. METHODS. Anonymized data from 884 children in the International Collaborative Gaucher Group Gaucher Registry were analyzed to determine the effects of long-term enzyme replacement therapy with alglucerase or imiglucerase on hematologic and visceral manifestations, linear growth, and skeletal disease. The parameters measured were hemoglobin levels, platelet counts, spleen and liver volumes, z scores for height and bone mineral density, and reports of bone pain and bone crises. RESULTS. The median height z score for the study population was −1.4 at baseline. After 8 years of treatment, the median height approximated the median value for the normal population. Anemia, although not severe, was present in >50% of patients at baseline and resolved for all patients after 8 years of treatment. More than 50% of patients had platelet counts of 95% had platelet counts above this level after 8 years of treatment. Liver and spleen volumes decreased over 8 years of treatment. The mean bone mineral density z score was −0.34 at baseline, and values normalized within 6.6 years of treatment. Seventeen percent of patients reported a bone crisis before treatment and in the first 2 years of treatment, but no bone crises were reported after 2 years of enzyme replacement therapy. Few patients (2.5%) without bone crises before enzyme replacement therapy had a crisis after the start of treatment. CONCLUSIONS. These longitudinal data quantitate the benefits of continuous enzyme replacement therapy with alglucerase/imiglucerase for children with Gaucher disease type 1. Within 8 years of enzyme replacement therapy, most clinical parameters studied became normal or nearly normal.